Table of Contents 1 Peptide Cancer Vaccine Market Overview 1.1 Product Overview and Scope of Peptide Cancer Vaccine 1.2 Peptide Cancer Vaccine Segment by Type 1.2.1 Global Peptide Cancer Vaccine Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Type I 1.2.3 Type II 1.3 Peptide Cancer Vaccine Segment by Application 1.3.1 Peptide Cancer Vaccine Sales Comparison by Application: 2020 VS 2026 1.3.2 Breast Cancer 1.3.3 Lung Cancer 1.3.4 Melanoma 1.3.5 Prostate Cancer 1.3.6 Others 1.4 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts 1.4.1 Global Peptide Cancer Vaccine Revenue 2015-2026 1.4.2 Global Peptide Cancer Vaccine Sales 2015-2026 1.4.3 Peptide Cancer Vaccine Market Size by Region: 2020 Versus 2026 2 Global Peptide Cancer Vaccine Market Competition by Manufacturers 2.1 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2015-2020) 2.2 Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2015-2020) 2.3 Global Peptide Cancer Vaccine Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Peptide Cancer Vaccine Manufacturing Sites, Area Served, Product Type 2.5 Peptide Cancer Vaccine Market Competitive Situation and Trends 2.5.1 Peptide Cancer Vaccine Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Peptide Cancer Vaccine Players (Opinion Leaders) 3 Peptide Cancer Vaccine Retrospective Market Scenario by Region 3.1 Global Peptide Cancer Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Peptide Cancer Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Peptide Cancer Vaccine Market Facts & Figures by Country 3.3.1 North America Peptide Cancer Vaccine Sales by Country 3.3.2 North America Peptide Cancer Vaccine Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Peptide Cancer Vaccine Market Facts & Figures by Country 3.4.1 Europe Peptide Cancer Vaccine Sales by Country 3.4.2 Europe Peptide Cancer Vaccine Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Region 3.5.1 Asia Pacific Peptide Cancer Vaccine Sales by Region 3.5.2 Asia Pacific Peptide Cancer Vaccine Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country 3.6.1 Latin America Peptide Cancer Vaccine Sales by Country 3.6.2 Latin America Peptide Cancer Vaccine Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country 3.7.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country 3.7.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Peptide Cancer Vaccine Historic Market Analysis by Type 4.1 Global Peptide Cancer Vaccine Sales Market Share by Type (2015-2020) 4.2 Global Peptide Cancer Vaccine Revenue Market Share by Type (2015-2020) 4.3 Global Peptide Cancer Vaccine Price Market Share by Type (2015-2020) 4.4 Global Peptide Cancer Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Peptide Cancer Vaccine Historic Market Analysis by Application 5.1 Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2020) 5.2 Global Peptide Cancer Vaccine Revenue Market Share by Application (2015-2020) 5.3 Global Peptide Cancer Vaccine Price by Application (2015-2020) 6 Company Profiles and Key Figures in Peptide Cancer Vaccine Business 6.1 TapImmune 6.1.1 Corporation Information 6.1.2 TapImmune Description, Business Overview and Total Revenue 6.1.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.1.4 TapImmune Products Offered 6.1.5 TapImmune Recent Development 6.2 BrightPath Biotherapeutics 6.2.1 BrightPath Biotherapeutics Peptide Cancer Vaccine Production Sites and Area Served 6.2.2 BrightPath Biotherapeutics Description, Business Overview and Total Revenue 6.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.2.4 BrightPath Biotherapeutics Products Offered 6.2.5 BrightPath Biotherapeutics Recent Development 6.3 Ultimovacs 6.3.1 Ultimovacs Peptide Cancer Vaccine Production Sites and Area Served 6.3.2 Ultimovacs Description, Business Overview and Total Revenue 6.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Ultimovacs Products Offered 6.3.5 Ultimovacs Recent Development 6.4 Sellas 6.4.1 Sellas Peptide Cancer Vaccine Production Sites and Area Served 6.4.2 Sellas Description, Business Overview and Total Revenue 6.4.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Sellas Products Offered 6.4.5 Sellas Recent Development 6.5 Boston Biomedical 6.5.1 Boston Biomedical Peptide Cancer Vaccine Production Sites and Area Served 6.5.2 Boston Biomedical Description, Business Overview and Total Revenue 6.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Boston Biomedical Products Offered 6.5.5 Boston Biomedical Recent Development 6.6 Imugene 6.6.1 Imugene Peptide Cancer Vaccine Production Sites and Area Served 6.6.2 Imugene Description, Business Overview and Total Revenue 6.6.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.6.4 Imugene Products Offered 6.6.5 Imugene Recent Development 6.7 VAXON Biotech 6.6.1 VAXON Biotech Peptide Cancer Vaccine Production Sites and Area Served 6.6.2 VAXON Biotech Description, Business Overview and Total Revenue 6.6.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.4.4 VAXON Biotech Products Offered 6.7.5 VAXON Biotech Recent Development 6.8 Generex Biotechnology 6.8.1 Generex Biotechnology Peptide Cancer Vaccine Production Sites and Area Served 6.8.2 Generex Biotechnology Description, Business Overview and Total Revenue 6.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Generex Biotechnology Products Offered 6.8.5 Generex Biotechnology Recent Development 6.9 ISA Pharmaceuticals 6.9.1 ISA Pharmaceuticals Peptide Cancer Vaccine Production Sites and Area Served 6.9.2 ISA Pharmaceuticals Description, Business Overview and Total Revenue 6.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.9.4 ISA Pharmaceuticals Products Offered 6.9.5 ISA Pharmaceuticals Recent Development 6.10 OncoTherapy Science 6.10.1 OncoTherapy Science Peptide Cancer Vaccine Production Sites and Area Served 6.10.2 OncoTherapy Science Description, Business Overview and Total Revenue 6.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.10.4 OncoTherapy Science Products Offered 6.10.5 OncoTherapy Science Recent Development 6.11 Immatics 6.11.1 Immatics Peptide Cancer Vaccine Production Sites and Area Served 6.11.2 Immatics Peptide Cancer Vaccine Description, Business Overview and Total Revenue 6.11.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020) 6.11.4 Immatics Products Offered 6.11.5 Immatics Recent Development 7 Peptide Cancer Vaccine Manufacturing Cost Analysis 7.1 Peptide Cancer Vaccine Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Peptide Cancer Vaccine 7.4 Peptide Cancer Vaccine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Peptide Cancer Vaccine Distributors List 8.3 Peptide Cancer Vaccine Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Peptide Cancer Vaccine Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Peptide Cancer Vaccine by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Peptide Cancer Vaccine by Type (2021-2026) 10.2 Peptide Cancer Vaccine Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Peptide Cancer Vaccine by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Peptide Cancer Vaccine by Application (2021-2026) 10.3 Peptide Cancer Vaccine Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Peptide Cancer Vaccine by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Peptide Cancer Vaccine by Region (2021-2026) 10.4 North America Peptide Cancer Vaccine Estimates and Projections (2021-2026) 10.5 Europe Peptide Cancer Vaccine Estimates and Projections (2021-2026) 10.6 Asia Pacific Peptide Cancer Vaccine Estimates and Projections (2021-2026) 10.7 Latin America Peptide Cancer Vaccine Estimates and Projections (2021-2026) 10.8 Middle East and Africa Peptide Cancer Vaccine Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Peptide Cancer Vaccine Sales (K Doses) Growth Rate Comparison by Type (2015-2026) Table 2. Global Peptide Cancer Vaccine Sales (K Doses) Comparison by Application: 2020 VS 2026 Table 3. Global Peptide Cancer Vaccine Market Size by Type (K Doses) (US$ Million) (2020 VS 2026) Table 4. Global Key Peptide Cancer Vaccine Manufacturers Covered in This Study Table 5. Global Peptide Cancer Vaccine Sales (K Doses) by Manufacturers (2015-2020) Table 6. Global Peptide Cancer Vaccine Sales Share by Manufacturers (2015-2020) Table 7. Global Peptide Cancer Vaccine Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Peptide Cancer Vaccine Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Peptide Cancer Vaccine Average Price (USD/Dose) of Key Manufacturers (2015-2020) Table 10. Manufacturers Peptide Cancer Vaccine Sales Sites and Area Served Table 11. Manufacturers Peptide Cancer Vaccine Product Types Table 12. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2019) Table 14.Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Peptide Cancer Vaccine Players Table 16. Global Peptide Cancer Vaccine Sales (K Doses) by Region (2015-2020) Table 17. Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2020) Table 18. Global Peptide Cancer Vaccine Revenue (Million US$) by Region (2015-2020) Table 19. Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020) Table 20. North America Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses) Table 21. North America Peptide Cancer Vaccine Sales Market Share by Country (2015-2020) Table 22. North America Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million) Table 23. North America Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020) Table 24. Europe Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses) Table 25. Europe Peptide Cancer Vaccine Sales Market Share by Country (2015-2020) Table 26. Europe Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Peptide Cancer Vaccine Sales by Region (2015-2020) (K Doses) Table 29. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Peptide Cancer Vaccine Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020) Table 32. Latin America Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses) Table 33. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2015-2020) Table 34. Latin America Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2015-2020) (K Doses) Table 37. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country (2015-2020) Table 40. Global Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020) Table 41. Global Peptide Cancer Vaccine Sales Share by Type (2015-2020) Table 42. Global Peptide Cancer Vaccine Revenue (Million US$) by Type (2015-2020) Table 43. Global Peptide Cancer Vaccine Revenue Share by Type (2015-2020) Table 44. Global Peptide Cancer Vaccine Price (USD/Dose) by Type (2015-2020) Table 45. Global Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020) Table 46. Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2020) Table 47. Global Peptide Cancer Vaccine Sales Growth Rate by Application (2015-2020) Table 48. TapImmune Peptide Cancer Vaccine Corporation Information Table 49. TapImmune Description and Business Overview Table 50. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 51. TapImmune Main Product Table 52. TapImmune Recent Development Table 53. BrightPath Biotherapeutics Peptide Cancer Vaccine Corporation Information Table 54. BrightPath Biotherapeutics Corporation Information Table 55. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 56. BrightPath Biotherapeutics Main Product Table 57. BrightPath Biotherapeutics Recent Development Table 58. Ultimovacs Peptide Cancer Vaccine Corporation Information Table 59. Ultimovacs Corporation Information Table 60. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 61. Ultimovacs Main Product Table 62. Ultimovacs Recent Development Table 63. Sellas Peptide Cancer Vaccine Corporation Information Table 64. Sellas Corporation Information Table 65. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 66. Sellas Main Product Table 67. Sellas Recent Development Table 68. Boston Biomedical Peptide Cancer Vaccine Corporation Information Table 69. Boston Biomedical Corporation Information Table 70. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 71. Boston Biomedical Main Product Table 72. Boston Biomedical Recent Development Table 73. Imugene Peptide Cancer Vaccine Corporation Information Table 74. Imugene Corporation Information Table 75. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 76. Imugene Main Product Table 77. Imugene Recent Development Table 78. VAXON Biotech Peptide Cancer Vaccine Corporation Information Table 79. VAXON Biotech Corporation Information Table 80. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 81. VAXON Biotech Main Product Table 82. VAXON Biotech Recent Development Table 83. Generex Biotechnology Peptide Cancer Vaccine Corporation Information Table 84. Generex Biotechnology Corporation Information Table 85. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 86. Generex Biotechnology Main Product Table 87. Generex Biotechnology Recent Development Table 88. ISA Pharmaceuticals Peptide Cancer Vaccine Corporation Information Table 89. ISA Pharmaceuticals Corporation Information Table 90. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 91. ISA Pharmaceuticals Main Product Table 92. ISA Pharmaceuticals Recent Development Table 93. OncoTherapy Science Peptide Cancer Vaccine Corporation Information Table 94. OncoTherapy Science Corporation Information Table 95. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 96. OncoTherapy Science Main Product Table 97. OncoTherapy Science Recent Development Table 98. Immatics Peptide Cancer Vaccine Corporation Information Table 99. Immatics Corporation Information Table 100. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million US$), Price (USD/Dose) and Gross Margin (2015-2020) Table 101. Immatics Main Product Table 102. Immatics Recent Development Table 103. Sales Base and Market Concentration Rate of Raw Material Table 104. Key Suppliers of Raw Materials Table 105. Peptide Cancer Vaccine Distributors List Table 106. Peptide Cancer Vaccine Customers List Table 107. Market Key Trends Table 108. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 109. Key Challenges Table 110. Global Peptide Cancer Vaccine Sales (K Doses) Forecast by Type (2021-2026) Table 111. Global Peptide Cancer Vaccine Sales Market Share Forecast by Type (2021-2026) Table 112. Global Peptide Cancer Vaccine Revenue (Million US$) Forecast by Type (2021-2026) Table 113. Global Peptide Cancer Vaccine Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 114. Global Peptide Cancer Vaccine Sales (K Doses) Forecast by Application (2021-2026) Table 115. Global Peptide Cancer Vaccine Revenue (Million US$) Forecast by Application (2021-2026) Table 116. Global Peptide Cancer Vaccine Sales (K Doses) Forecast by Region (2021-2026) Table 117. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2021-2026) Table 118. Global Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026) (US$ Million) Table 119. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Region (2021-2026) Table 120. Research Programs/Design for This Report Table 121. Key Data Information from Secondary Sources Table 122. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Peptide Cancer Vaccine Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Type: 2020 VS 2026 Figure 3. Type I Product Picture Figure 4. Type II Product Picture Figure 5. Global Peptide Cancer Vaccine Consumption Market Share by Application: 2020 VS 2026 Figure 6. Breast Cancer Figure 7. Lung Cancer Figure 8. Melanoma Figure 9. Prostate Cancer Figure 10. Others Figure 11. Global Peptide Cancer Vaccine Market Size 2015-2026 (US$ Million) Figure 12. Global Peptide Cancer Vaccine Sales Capacity (K Doses) (2015-2026) Figure 13. Global Peptide Cancer Vaccine Market Size Market Share by Region: 2020 Versus 2026 Figure 14. Peptide Cancer Vaccine Sales Share by Manufacturers in 2020 Figure 15. Global Peptide Cancer Vaccine Revenue Share by Manufacturers in 2019 Figure 16. The Global 5 and 10 Largest Players: Market Share by Peptide Cancer Vaccine Revenue in 2019 Figure 17. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 18. Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2020) Figure 19. Global Peptide Cancer Vaccine Sales Market Share by Region in 2019 Figure 20. Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020) Figure 21. Global Peptide Cancer Vaccine Revenue Market Share by Region in 2019 Figure 22. North America Peptide Cancer Vaccine Sales Market Share by Country in 2019 Figure 23. North America Peptide Cancer Vaccine Revenue Market Share by Country in 2019 Figure 24. U.S. Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 25. U.S. Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 26. Canada Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 27. Canada Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 28. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2019 Figure 29. Europe Peptide Cancer Vaccine Revenue Market Share by Country in 2019 Figure 30. Germany Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 31. Germany Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 32. France Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 33. France Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 34. U.K. Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 35. U.K. Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 36. Italy Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 37. Italy Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 38. Russia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 39. Russia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 40. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Region in 2019 Figure 41. Asia Pacific Peptide Cancer Vaccine Revenue Market Share by Region in 2019 Figure 42. China Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 43. China Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 44. Japan Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 45. Japan Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. South Korea Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 47. South Korea Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. India Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 49. India Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 50. Australia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 51. Australia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 52. Taiwan Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 53. Taiwan Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. Indonesia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 55. Indonesia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. Thailand Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 57. Thailand Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Malaysia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 59. Malaysia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Philippines Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 61. Philippines Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Vietnam Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 63. Vietnam Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 64. Latin America Peptide Cancer Vaccine Sales Market Share by Country in 2019 Figure 65. Latin America Peptide Cancer Vaccine Revenue Market Share by Country in 2019 Figure 66. Mexico Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 67. Mexico Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Brazil Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 69. Brazil Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. Argentina Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 71. Argentina Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country in 2019 Figure 73. Middle East and Africa Peptide Cancer Vaccine Revenue Market Share by Country in 2019 Figure 74. Turkey Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 75. Turkey Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Saudi Arabia Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 77. Saudi Arabia Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. U.A.E Peptide Cancer Vaccine Sales Growth Rate (2015-2020) (K Doses) Figure 79. U.A.E Peptide Cancer Vaccine Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Sales Market Share of Peptide Cancer Vaccine by Type (2015-2020) Figure 81. Sales Market Share of Peptide Cancer Vaccine by Type in 2019 Figure 82. Revenue Share of Peptide Cancer Vaccine by Type (2015-2020) Figure 83. Revenue Market Share of Peptide Cancer Vaccine by Type in 2019 Figure 84. Global Peptide Cancer Vaccine Sales Growth by Type (2015-2020) (K Doses) Figure 85. Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2020) Figure 86. Global Peptide Cancer Vaccine Sales Market Share by Application in 2019 Figure 87. Global Revenue Share of Peptide Cancer Vaccine by Application (2015-2020) Figure 88. Global Revenue Share of Peptide Cancer Vaccine by Application in 2020 Figure 89. TapImmune Total Revenue (US$ Million): 2019 Compared with 2018 Figure 90. BrightPath Biotherapeutics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 91. Ultimovacs Total Revenue (US$ Million): 2019 Compared with 2018 Figure 92. Sellas Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. Boston Biomedical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Imugene Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. VAXON Biotech Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Generex Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. ISA Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 98. OncoTherapy Science Total Revenue (US$ Million): 2019 Compared with 2018 Figure 99. Immatics Total Revenue (US$ Million): 2019 Compared with 2018 Figure 100. Price Trend of Key Raw Materials Figure 101. Manufacturing Cost Structure of Peptide Cancer Vaccine Figure 102. Manufacturing Process Analysis of Peptide Cancer Vaccine Figure 103. Peptide Cancer Vaccine Industrial Chain Analysis Figure 104. Channels of Distribution Figure 105. Distributors Profiles Figure 106. Porter's Five Forces Analysis Figure 107. North America Peptide Cancer Vaccine Sales (K Doses) and Growth Rate Forecast (2021-2026) Figure 108. North America Peptide Cancer Vaccine Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 109. Europe Peptide Cancer Vaccine Sales (K Doses) and Growth Rate Forecast (2021-2026) Figure 110. Europe Peptide Cancer Vaccine Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 111. Latin America Peptide Cancer Vaccine Sales (K Doses) and Growth Rate Forecast (2021-2026) Figure 112. Latin America Peptide Cancer Vaccine Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 113. Middle East and Africa Peptide Cancer Vaccine Sales (K Doses) and Growth Rate Forecast (2021-2026) Figure 114. Middle East and Africa Peptide Cancer Vaccine Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 115. Asia Pacific Peptide Cancer Vaccine Sales (K Doses) and Growth Rate Forecast (2021-2026) Figure 116. Asia Pacific Peptide Cancer Vaccine Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 117. Bottom-up and Top-down Approaches for This Report Figure 118. Data Triangulation Figure 119. Key Executives Interviewed

TapImmune BrightPath Biotherapeutics Ultimovacs Sellas Boston Biomedical Imugene VAXON Biotech Generex Biotechnology ISA Pharmaceuticals OncoTherapy Science Immatics